Clinical trialNCT04079179RecruitingPhase 2Interventional

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

SponsorCarl AllenEnrollment90Erdheim-Chester DiseaseHistiocytic Disorders, MalignantHistiocytic SarcomaJuvenile XanthogranulomaLangerhan's Cell HistiocytosisNeuro-Degenerative Disease+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Carl E Allen, MD, PhD
Baylor College of Medicine
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Phoenix Children'S Hospital
Phoenix, Arizona, United States
Recruiting
Arkansas Children'S Hospital
Little Rock, Arkansas, United States
Recruiting
Children'S Hospital of Orange County
Orange, California, United States
Recruiting
Ucsf Benioff Children'S Hospital
San Francisco, California, United States
Michelle L Hermiston, MD
Recruiting
Children'S National Hospital
Washington D.C., District of Columbia, United States
Recruiting
John Hopkins University School of Medicine
Baltimore, Maryland, United States
Recruiting
Dana Farber Cancer Institute, Boston Children'S
Boston, Massachusetts, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
Nacho Consortium
Memphis, Tennessee, United States
Not, yet, recruiting
Children'S Medical Center- Utsw
Dallas, Texas, United States
Recruiting
Texas Children'S Hospital
Houston, Texas, United States
Recruiting
University of Wisconsin-American Family Children'S Hospital
Madison, Wisconsin, United States
Terminated

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cobimetinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Apr 2021
Primary completion: 31 Dec 2025
Completion: 31 Dec 2029
Last update posted: 18 Sept 2025
Registered enrollment: 90
Registry id: NCT04079179

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.